97 related articles for article (PubMed ID: 24854110)
1. Rosuvastatin inhibits TIMP-2 and promotes myocardial angiogenesis.
Siddiqui AJ; Gustafsson T; Sylven C; Crisby M
Pharmacology; 2014; 93(3-4):178-84. PubMed ID: 24854110
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-II and rosuvastatin influence matrix remodeling in human mesangial cells via metalloproteinase modulation.
Solini A; Rossi C; Santini E; Madec S; Salvati A; Ferrannini E
J Hypertens; 2011 Oct; 29(10):1930-9. PubMed ID: 21881526
[TBL] [Abstract][Full Text] [Related]
3. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.
Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J
Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896
[TBL] [Abstract][Full Text] [Related]
4. Rosuvastatin reduces gliosis and the accelerated weight gain observed in WT and ApoE-/- mice exposed to a high cholesterol diet.
Famer D; Crisby M
Neurosci Lett; 2007 May; 419(1):68-73. PubMed ID: 17433542
[TBL] [Abstract][Full Text] [Related]
5. Yellow wine polyphenolic compounds inhibit matrix metalloproteinase-2, -9 expression and improve atherosclerotic plaque in LDL-receptor-knockout mice.
Zhai X; Chi J; Tang W; Ji Z; Zhao F; Jiang C; Lv H; Guo H
J Pharmacol Sci; 2014; 125(2):132-41. PubMed ID: 24859779
[TBL] [Abstract][Full Text] [Related]
6. [Impact of rosuvastatin on atherosclerosis lesions in apolipoprotein E knockout mice].
Luo RN; Tao LJ; Zhou J; Wang R; Lu MM; Fu X
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Aug; 39(8):743-8. PubMed ID: 22169423
[TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice.
Enomoto S; Sata M; Fukuda D; Nakamura K; Nagai R
Biomed Pharmacother; 2009 Jan; 63(1):19-26. PubMed ID: 18162361
[TBL] [Abstract][Full Text] [Related]
8. Effect of combined treatment with rosuvastatin and protein kinase Cβ2 inhibitor on angiogenesis following myocardial infarction in diabetic rats.
Huang D; Wang FB; Guo M; Li S; Yan ML; Yu T; Wei M; Li JB
Int J Mol Med; 2015 Mar; 35(3):829-38. PubMed ID: 25524396
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis.
Chen J; Li D; Schaefer RF; Mehta JL
J Cardiovasc Pharmacol; 2004 Oct; 44(4):446-52. PubMed ID: 15454852
[TBL] [Abstract][Full Text] [Related]
10. The complementary effects of atorvastatin and exercise treatment on the composition and stability of the atherosclerotic plaques in ApoE knockout mice.
Moustardas P; Kadoglou NP; Katsimpoulas M; Kapelouzou A; Kostomitsopoulos N; Karayannacos PE; Kostakis A; Liapis CD
PLoS One; 2014; 9(9):e108240. PubMed ID: 25264981
[TBL] [Abstract][Full Text] [Related]
11. Effects of rosuvastatin on the production and activation of matrix metalloproteinase-2 and migration of cultured rat vascular smooth muscle cells induced by homocysteine.
Shi YF; Chi JF; Tang WL; Xu FK; Liu LB; Ji Z; Lv HT; Guo HY
J Zhejiang Univ Sci B; 2013 Aug; 14(8):696-704. PubMed ID: 23897788
[TBL] [Abstract][Full Text] [Related]
12. Acipimox attenuates atherosclerosis and enhances plaque stability in ApoE-deficient mice fed a palmitate-rich diet.
Jin F; Jiang S; Yang D; Zhang X; Yang Y; Zhang Y; Li K; Yang Y; Ma S
Biochem Biophys Res Commun; 2012 Nov; 428(1):86-92. PubMed ID: 23058919
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury.
Schäfer K; Kaiser K; Konstantinides S
Thromb Haemost; 2005 Jan; 93(1):145-52. PubMed ID: 15630505
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice.
Monetti M; Canavesi M; Camera M; Parente R; Paoletti R; Tremoli E; Corsini A; Bellosta S
Pharmacol Res; 2007 May; 55(5):441-9. PubMed ID: 17350858
[TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin promotes angiogenesis and reverses isoproterenol-induced acute myocardial infarction in rats: role of iNOS and VEGF.
Zaitone SA; Abo-Gresha NM
Eur J Pharmacol; 2012 Sep; 691(1-3):134-42. PubMed ID: 22732653
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilisation and recruitment in apolipoprotein E knockout mice.
Schroeter MR; Humboldt T; Schäfer K; Konstantinides S
Atherosclerosis; 2009 Jul; 205(1):63-73. PubMed ID: 19111832
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent effect of rosuvastatin in the regulation of metalloproteinase expression.
Sapienza P; Borrelli V; Sterpetti AV; Dinicola S; Tartaglia E; di Marzo L
Ann Vasc Surg; 2011 Aug; 25(6):823-9. PubMed ID: 21620672
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-leiden mice.
Delsing DJ; Post SM; Groenendijk M; Solaas K; van der Boom H; van Duyvenvoorde W; de Wit EC; Bloks VW; Kuipers F; Havekes LM; Princen HM
J Cardiovasc Pharmacol; 2005 Jan; 45(1):53-60. PubMed ID: 15613980
[TBL] [Abstract][Full Text] [Related]
19. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.
Giunti S; Calkin AC; Forbes JM; Allen TJ; Thomas MC; Cooper ME; Jandeleit-Dahm KA
Am J Physiol Renal Physiol; 2010 Sep; 299(3):F528-35. PubMed ID: 20554645
[TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin improves hepatopulmonary syndrome through inhibition of inflammatory angiogenesis of lung.
Chang CC; Wang SS; Hsieh HG; Lee WS; Chuang CL; Lin HC; Lee FY; Lee SD; Huang HC
Clin Sci (Lond); 2015 Sep; 129(6):449-60. PubMed ID: 25940601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
